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Abstract
 
The prevention and treatment of prevalent infectious diseases and tumors should benefit from
improvements in the induction of antigen-specific T cell immunity. To assess the potential of
antigen targeting to dendritic cells to improve immunity, we incorporated ovalbumin protein
into a monoclonal antibody to the DEC-205 receptor, an endocytic receptor that is abundant
on these cells in lymphoid tissues. Simultaneously, we injected agonistic 
 
 
 
-CD40 antibody to
mature the dendritic cells. We found that a single low dose of antibody-conjugated ovalbumin
initiated immunity from the naive CD4
 
 
 
 and CD8
 
 
 
 T cell repertoire. Unexpectedly, the
 
 
 
DEC-205 antigen conjugates, given s.c., targeted to dendritic cells systemically and for long
periods, and ovalbumin peptide was presented on MHC class I for 2 weeks. This was associated
with stronger CD8
 
 
 
 T cell–mediated immunity relative to other forms of antigen delivery,
even when the latter was given at a thousand times higher doses. In parallel, the mice showed
enhanced resistance to an established rapidly growing tumor and to viral infection at a mucosal
site. By better harnessing the immunizing functions of maturing dendritic cells, antibody-mediated
antigen targeting via the DEC-205 receptor increases the efficiency of vaccination for T cell
immunity, including systemic and mucosal resistance in disease models.
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Introduction
 
For many diseases that lead to high mortality and morbidity,
such as AIDS and malaria, it is likely that vaccines will need
to elicit strong T cell–mediated immunity composed of
IFN-
 
 
 
 secreting CD4
 
 
 
 helper and CD8
 
 
 
 cytolytic T lym-
phocytes (for reviews see references 1–4). To induce such
responses, it would be valuable to harness the DC system of
antigen-presenting cells (5, 6). At least three sets of DC
functions are pertinent. First, DCs efficiently process antigens,
including complex microbes and tumor cells, and display
these on both MHC class I and II products to CD8
 
 
 
 and
CD4
 
 
 
 T cells, respectively (7, 8). Second, DCs become
potent stimulators of immunity after undergoing a complex
differentiation or maturation program in response to a
panel of stimuli including microbial ligands for toll-like
receptors (9, 10), innate lymphocytes (11, 12), and CD40
ligation (13). Third, DCs localize to the T cell areas of lym-
phoid organs (14, 15), where they expand antigen-specific
T cells (16–18) and when mature, induce IFN-
 
 
 
–producing
helper and killer T cells (19, 20).
We set out to marshal these features of DCs to improve
vaccination. Our strategy was to target antigens to the
DEC-205 endocytosis receptor. It is expressed at high levels
on lymphoid tissue DCs (21–23) and greatly enhances the
efficiency of antigen presentation (24, 25). We followed
the consequences of DEC-205 antigen targeting in naive
mice with a polyclonal T cell repertoire. We will show that
a single low s.c. dose of a protein-based vaccine is able to
charge DCs with antigen systemically and for long periods,
particularly on MHC class I products. In parallel, naive
mice develop immunity, including CD8
 
 
 
 T cell–mediated
immunity, which is considerably enhanced relative to prior
 
Address correspondence to Ralph M. Steinman, Laboratory of Cellular
Physiology and Immunology, The Rockefeller University, New York,
NY 10021-6399. Phone: (212) 327-8106; Fax: (212) 327-8875; email:
Steinma@mail.rockefeller.edu
 
Abbreviations used in this paper:
 
 CFSE, carboxyfluorescein diacetate succi-
nimidyl ester; MESNA, 2-mercaptoethanesulfonic acid sodium salt;
OVA, ovalbumin. 
Improved Vaccination with DC Antigen Targeting
 
816
 
methods of immunization with 1,000-fold higher doses of
antigen and is associated with stronger protection in anti-
viral and anti-tumor models.
 
Materials and Methods
 
Antibodies and Reagents.
 
 Alexa
 
488
 
-conjugated 
 
 
 
DEC-205
(NLDC-145), 
 
 
 
OVA (3A11.1), and isotype control (III/10) anti-
bodies were prepared using the Alexa Fluor
 
®
 
 488 protein labeling
kit (Molecular Probes).
 
Mice. 
 
Adult female C57BL/6 (B6) mice, and CD4
 
 
 
/
 
 
 
 and
CD8
 
 
 
/
 
 
 
 B6 knockouts, were purchased from Jackson Immu-
noResearch Laboratories. Ovalbumin (OVA)-specific, TCR-
transgenic CD45.1
 
 
 
 OT-I and CD45.1
 
 
 
 OT-II mice were used
as described previously (20). DEC-205
 
 
 
/
 
 
 
 mice were provided
by Dr. M. Nussenzweig (The Rockefeller University, New
York, NY).
 
Conjugation of OVA to Monovalent Monoclonal Antibodies.  
 
Mono-
valent IgG’s were conjugated to LPS-free OVA (Seikagaku Corp.)
that had been activated with succinimidyl 4-(
 
N
 
-maleimido-
methyl) cyclohexane-1-carboxylate (SMCC; Pierce Chemical Co.)
according to the manufacturer’s protocol. In brief, the antibodies
were reduced using 100 mM 2-mercaptoethanesulfonic acid so-
dium salt (MESNA; Sigma-Aldrich) for 30 min at 37
 
 
 
C and sepa-
rated from the reducing agent over a desalting column. Then the
activated OVA was mixed with the reduced antibodies overnight
at 4
 
 
 
C. The antibody:OVA conjugates were passed over a protein
G column to remove unconjugated OVA, concentrated by spin
columns, and evaluated by spectrophotometry and SDS-PAGE.
Monovalent IgG:OVA conjugates were characterized by SDS-
PAGE and Western blotting. Quantification of the OVA content
of the conjugates was achieved by comparison with known quan-
tities of OVA on the same blot detected with an HRP-conju-
gated polyclonal rabbit anti-OVA antibody (Research Diagnos-
tics, Inc.).
 
Purification of DCs and Antigen-specific T Cells. 
 
Single cell
suspensions were prepared from lymph nodes or spleen with 400
U/ml collagenase D (Roche) for 25 min and CD11c
 
 
 
 cells puri-
fied by MACS
 
®
 
. OVA-specific transgenic CD8
 
 
 
 or CD4
 
 
 
 T
cells were prepared from lymph node or spleen cell suspensions
of OT-I or OT-II mice using negative selection with hybridoma
supernatants directed against MHC class II, F4/80, B220, NK
1.1, and CD4 or CD8 and goat anti–rat Dynabeads
 
®
 
 (Dynal) at a
ratio of four beads to one target cell.
 
Antigen Targeting and Maturation of DCs In Vivo. 
 
Mice were
injected s.c. in the paws with OVA protein, or Ig conjugates of
OVA protein, without or with a stimulus for DC maturation,
which was the 1C10 agonistic 
 
 
 
CD40 antibody (26) injected i.p.
at 25–50 
 
 
 
g/mouse as described previously (20).
 
Assays with TCR-transgenic T Cells to Monitor Antigen Presenta-
tion on MHC Class I and II Products. 
 
In vitro antigen presenta-
tion assays were performed by adding CD11c
 
 
 
 DCs, selected
from lymph nodes and spleens of OVA-treated mice, to 10
 
5
 
 OT-I
or OT-II T cells in round bottom 96-well plates (1 DC:3 T cell
ratio). At 48 h, [
 
3
 
H]thymidine (1 
 
 
 
Ci; Amersham Biosciences)
was added for 12 h to detect incorporation into DNA. In vivo as-
says were performed by injecting 10
 
6
 
 CD45.1
 
 
 
 OT-I or OT-II T
cells that had been labeled at 10
 
7
 
 cells/ml with 5 
 
 
 
M carboxyflu-
orescein diacetate succinimidyl ester (CFSE; Molecular Probes)
for 10 min at 37
 
 
 
C.
 
Assays for OVA Immunization.
 
Proliferation of primed CD4
 
 
 
or CD8
 
 
 
 T cells was evaluated by labeling bulk spleen suspen-
 
sions with CFSE as above (but at 1 
 
 
 
M) and restimulating
with LPS-free OVA (500 
 
 
 
g/ml) for 5 d in 24-well dishes at
2.5 
 
 
 
 10
 
6
 
 cells/well. Cultures were then washed, stained for
CD4 and CD8 and evaluated for proliferation by flow cytometry.
ELISPOT assays were performed by restimulating spleen suspen-
sions for 2 d with H-2K
 
b
 
-restricted peptide (SIINFEKL; 1.0 
 
 
 
M)
or an I-A
 
b
 
-restricted peptide (LSQAVHAAHAEINEAGR; 1.0
 
 
 
M). The in vivo response of OVA-specific CD8
 
 
 
 T cells was
evaluated by staining with K
 
b
 
-SIINFEKL–PE tetramers (pro-
vided by Dr. E. Pamer, Memorial Sloan Kettering Institute, New
York, NY) and CD62L for 1 h at 4
 
 
 
C. Also IFN-
 
 
 
–producing
effector cells were evaluated by culturing 5 
 
 
 
 10
 
6
 
 lymph node or
spleen cells with SIINFEKL peptide (1.0 
 
 
 
M) for 6 h in the pres-
ence of brefeldin A (5 
 
 
 
g/ml; Sigma-Aldrich). Cells were then
harvested, stained for extracellular CD8, and then stained for cy-
tokines with the BD intracellular cytokine staining starter kit
(Becton Dickinson). In vivo CTL assays were performed as described
(27) by injecting 1:1 mixtures of peptide-pulsed and -unpulsed
syngeneic splenocytes (7 
 
 
 
 10
 
6
 
 each) and, 12–18 h later, specific lysis
quantified as {[1 - (ratio unprimed / ratio primed)] 
 
 
 
 100}, with
ratio determined as % CFSE
 
lo
 
/% CFSE
 
hi 
 
(28).
 
Vaccine-induced Resistance Assays. 
 
Tumor challenges were
performed with 5 
 
 
 
 10
 
6
 
 MO4, OVA-bearing B16 melanoma
cells injected s.c. on the right flank either 7 d before, or 30–90 d
after, immunization. Nontransduced B16 melanoma cells were
used as controls to show that immunity was OVA-dependent.
Challenge with recombinant vaccinia–OVA virus was performed
with 10
 
5
 
 PFU applied intranasally as described (29). 7 d later,
lungs were harvested, extracts prepared by physical disruption,
and viral titers evaluated by plaque forming assay on CV-1 cells.
Tumor data are expressed as average tumor size from groups of at
least five mice, where vaccinia titers as average 
 
 
 
 1 SD for groups
of at least five mice.
 
Results
 
Preparation of Monovalent 
 
 
 
DEC-205:OVA Conjugates
That More Efficiently Harness the Antigen-presenting Activity of
DCs In Vivo. 
 
We first modified a prior strategy to conju-
gate an antigen to a monoclonal antibody to the DEC-205
receptor (20). This antibody selectively targets to lymph
node DCs after s.c. injection (19, 20). With the mild-
reducing agent MESNA to cleave interheavy chain disulfide
bonds, we produced monovalent fragments of the antibody
(Fig. 1 A). The exposed sulfhydryls of nearly all the anti-
body molecules could then be cross-linked with SMCC-
activated OVA (see Conjugation of OVA to Monovalent
Monoclonal Antibodies section in Materials and Methods),
yielding 132-kD conjugates containing OVA and rat IgG
(Fig. 1 B). The 
 
 
 
DEC-205:OVA conjugates, as well as
conjugates produced with an isotype matched nonreactive
antibody called III/10, were subjected to Western blotting
along side known quantities of OVA protein to quantify
the amount of OVA in the conjugates, generally 
 
 
 
10% of
the total protein (unpublished data). When the monovalent
 
 
 
DEC-205:OVA conjugates were injected s.c., the OVA
was presented to MHC class I– and MHC class II–
restricted T cells in vivo, as assessed with OVA-specific re-
porter T cells from CD8
 
 
 
 OT-I and CD4
 
 
 
 OT-II, TCR-
transgenic mice. Both types of T cells, which were labeled 
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with CFSE before injection, proliferated vigorously (five to
seven division cycles) in response to 
 
 
 
DEC-205:OVA but
not to isotype matched III/10–OVA conjugates (Fig. 1 C).
When we compared the efficacy of achieving antigen pre-
sentation in vivo by monovalent antibody targeted OVA
and soluble OVA, the conjugated OVA was 
 
 
 
1,000 times
more effective for MHC class I presentation and 
 
 
 
50 times
greater for MHC class II presentation (Fig. 1 C). For exam-
ple, 2,500 ng of soluble OVA did not elicit a proliferative
response from CD8
 
 
 
 OT-I T cells, but 2 ng of OVA in
 
 
 
DEC-205:OVA caused most of the T cells to enter multi-
ple cycles of division (Fig. 1 D). In DEC-205 knockout
mice (DEC-205
 
 
 
/
 
 
 
), presentation of 
 
 
 
DEC-205:OVA,
but not soluble unconjugated OVA, was abolished (Fig. 1
C), proving that presentation of 
 
 
 
DEC-205:OVA was
strictly dependent upon this endocytic receptor. Thus the
Figure 1. Characterization of
monoclonal IgG:OVA conju-
gates.  (A) IgG:OVA conjugates
at various stages of conjugation.
Nonreduced gel (left) of the
80-kD  monovalent IgG after
MESNA treatment, and reduced
and boiled (right) to show heavy
and light chains. (B) Western
analysis of antibody (DEC-205
and III/10 isotype control) OVA
conjugates. (C) C57BL/6 or
DEC-205 /  mice were injected
i.v. with 106 CFSE-labeled OT-I
or OT-II T cells and 24 h later
with either antibody conjugates
(DEC-205 and III/10 isotype
control at the same doses) con-
taining 50 ng of OVA or 25  g
soluble OVA s.c. 3 d later, prolif-
eration in lymph nodes was eval-
uated by flow cytometry. (D) As
in C, but graded doses of OVA
conjugated to IgG- or endotoxin-
free OVA were used. For the
III/10 isotype control, the highest
dose of conjugate with 250 ng of
OVA was used. Representative of
two or more experiments.
Figure 2.  DEC-205:OVA
with  CD40 primes both CD4 
and CD8  T cells in vivo. (A)
 DEC-205:OVA containing 500
ng of OVA was administered to
naive C57BL/6 mice s.c. with 25
 g of  CD40. 7 d later, spleen cell
suspensions were CFSE labeled
and restimulated in vitro for 5 d
with LPS-free OVA (500  g/ml)
to evaluate proliferation by
flow cytometry. (B) As in A,
but the cells were restimulated
with either SIINFEKL (1.0  M)
or LSQAVHAAHAEINEAGR
(2.0   M) peptides for 2 d and
IFN-  secretion evaluated by
ELISPOT. (C) Mice were immu-
nized with grade doses of OVA as
a soluble protein or conjugated
to   DEC-205. IFN  secretion
was evaluated after 7 d in the
lymph nodes and spleen as in B.
Representative of at least two
experiments.Improved Vaccination with DC Antigen Targeting 818
injection of antigen conjugated to a monovalent  DEC-
205 antibody markedly enhances the efficiency of antigen
presentation in vivo.
Immunization of CD4  and CD8  T Cells with a Combi-
nation of OVA Targeting to DCs and a CD40-based Matura-
tion Stimulus.  Previous studies had demonstrated the ca-
pacity for DEC-205–targeted antigens to immunize large
numbers of TCR-transgenic T cells in vivo, as long as anti-
gen was given together with an agonistic  CD40 mono-
clonal antibody to mature the lymph node DCs (19, 20).
We therefore tested if we could prime the endogenous na-
ive repertoire that contains a low frequency of antigen-spe-
cific T cells. We monitored the induction of immunity to
graded doses of antigen with two standard assays for im-
mune priming: T cell proliferation in response to antigen
and IFN- –secreting ELISPOTS. We first injected 500 ng
of OVA conjugated to  DEC-205 (5  g of antibody con-
jugate injected s.c. in four paws), in combination with 25
 g of  CD40. 7 d later, both CD4  and CD8  T cells
proliferated after in vitro restimulation with OVA protein
(Fig. 2 A). The proliferation was weak to undetectable in
control mice primed with  DEC-205:OVA alone,  CD40
alone, or a mixture of OVA and  CD40 (Fig. 2 A). The
mice also developed OVA-specific IFN- –secreting effec-
tor cells, with the CD8  response being more vigorous
than the CD4  response (Fig. 2 B). When we used the
ELISPOT assay to compare  DEC-205:OVA to OVA
(each together with  CD40), the targeted antibody was
 1,000 times more effective for immunizing naive mice
(Fig. 2 C). Therefore antigen targeting to DCs via DEC-
205, coupled with  CD40, greatly increases the efficiency
with which a protein initiates T cell–mediated immunity
from a polyclonal naive repertoire.
The Durability of the Effector CD8  T Cell Response When
Antigen Is Targeted to DCs.  We concentrated our subse-
quent studies on the CD8  response, because it is a special
challenge to be able to present nonreplicating antigens to
CD8  T cells in vivo and this would be valuable for the
design of safe nonreplicating and subunit vaccines. We gave
a single dose of 50–100 ng of OVA conjugated to  DEC-
205 (i.e., 0.5–1.0  g of total antibody:OVA protein per
mouse) together with 25  g of agonistic  CD40 s.c., and
then we monitored the development of effector T cells us-
ing assays for cytokine secretion and cytolytic activity. An-
tibody targeting to maturing DCs was able to elicit vigor-
ous IFN-  secretion by CD8  T cells in both the lymph
nodes and spleen, but in addition, the response was long
lived (Fig. 3 A). At all time points tested (14, 21, 60, and
90 d) after administration of a single dose  DEC-205:OVA
with  CD40, the CD8  splenocytes had been primed to
secrete IFN-  upon peptide restimulation (Fig. 3 A). Ad-
ministration of either the antigen ( DEC-205:OVA) or
DC maturation stimulus ( CD40) alone failed to elicit any
response (Fig. 3 A, left panels). To verify that the CD8  re-
sponse included cells with in vivo cytolytic function, we
injected a mixture of peptide pulsed and unpulsed synge-
neic splenocytes (7   106 cells each) 14 d after immuniza-
tion. Effective and specific CTLs were observed in the
lymph nodes (Fig. 3 B) and spleen (unpublished data), with
nearly all of the peptide-pulsed targets being eradicated
from these organs. The CTL responses were undiminished
in a CD4 /  mouse, but completely absent in CD8 / 
mice and DEC-205 /  mice (Fig. 3 B). CTL activity re-
mained vigorous 60 d after immunization (Fig. 3 C, 77%
lysis at day 60, compared with 93% lysis in Fig. 3 B at day
14), and even 90 d after immunization, CTLs were still de-
tected, although at lower levels (30% lysis; unpublished
data). These results indicate that a single immunization
with  DEC-205:OVA and  CD40 leads to the durable
formation of effector memory T cells.
The Immune Response to  DEC-205:OVA Is Greater Than
with Other Immunization Strategies.  To compare the DC-
targeting strategy with other immunization approaches that
are commonly used to induce strong T cell–mediated im-
munity to proteins, we studied (a) splenic DCs matured
and pulsed ex vivo with OVA (30, 31), as well as (b) free
antigens (OVA protein, OVA peptide, and  DEC-205:
OVA) suspended in CFA (32) or given together with
 CD40. 7 and 30 d after immunization, we evaluated the
expansion of OVA-specific T cells by MHC class I tet-
ramer staining in lymph node and spleen. At both time
points, the combination of  DEC-205:OVA with  CD40
was much more effective, especially if one examined the
spleen, a site for the accumulation of effector memory T
cells (Fig. 4 A). The frequency of antigen-binding CD8 
Figure 3.  DEC-205:OVA in combination with  CD40 induces durable
and strong OVA-specific responses by CD8  T cells. (A)  DEC-205:OVA
containing 50 ng of OVA was administered to naive C57BL/6 mice s.c.
with 25  g of  CD40. 14, 21, 60, and 90 d later, intracellular IFN- 
staining was evaluated by flow cytometry without or with OVA peptide
restimulation. Indicated percentages are percent IFN-   CD8  cells.
(B) Wild-type, DEC-205 / , CD8 / , and CD4 /  mice were treated as
in A. 14 d later, 7   106 of each, CFSE-labeled syngeneic splenocytes
pulsed with peptide (CFSEhi) or not (CFSElo), were injected i.v. to detect
active killer cells in the lymph nodes. (C) As in B, but mice were evaluated
after 60 d. Data are representative of two or more experiments.Bonifaz et al. 819
cells was much higher in response to 50 ng of OVA conju-
gated to  DEC-205 (5.4%) relative to 50  g soluble OVA,
injected along with either  CD40 (1.2%) or CFA (0.3%);
50  g preprocessed OVA peptide with  CD40 was even
less effective (Fig. 4 A). On day 7, the tetramer-positive
cells in the  DEC-205:OVA treated mice had down-regu-
lated CD62L confirming that these T cells were effectors
(Fig. 3) with the potential to migrate into peripheral tissues.
The degree of expansion of tetramer-positive cells corre-
lated closely with the production of functioning effector
cells assayed by IFN-  secretion, which again was much
higher after  DEC-205:OVA targeting relative to other
forms of antigen delivery (Fig. 4 B). These results indicate
that direct in vivo delivery of protein antigens to DCs is
more effective than several existing approaches for vaccine
priming of antigen-specific CD8  T cells.
Systemic and Prolonged Distribution of OVA after  DEC-
205 Targeting to DCs. To determine how DEC-205 tar-
geting improves antigen delivery in situ, the rate and persis-
tence of antibody loading of DCs in lymphoid tissues were
evaluated over time. The isotype-matched control III/10
antibody bound weakly if at all to DCs at all time points
(Fig. 5 A). In contrast, within 30 min of s.c. injection,
Alexa488
®-conjugated  DEC-205 began to load a sizable
fraction of the CD11c  DCs in the draining lymph nodes,
consistent with the direct movement of antibody from the
skin injection site via the protein-rich afferent lymph to the
lymph node. Unexpectedly, the  DEC-205 quickly ap-
peared on all of the CD8  DCs of the spleen (the CD8 
DC subset is also the DEC-205 high subset in spleen al-
though in lymph nodes, DEC-205 and CD8 expression are
not coordinate on certain DC subsets; 33, 34), indicating
that antibody was gaining access to the blood stream (Fig. 5
A, arrows). Considerable loading in the mesenteric lymph
node also was detectable, but at longer times after injection
(Fig. 5 A). By 6 h,  DEC-205 loaded at least 50% of the
draining lymph node DCs and  40% and  30% in the dis-
tal lymph node and spleen DCs, respectively. Interestingly,
 DEC-205 persisted on the DCs in all the organs for at
least 3 d after injection (Fig. 5 A, bottom). The presence of
OVA in the DCs of a draining lymph node and spleen was
also evident by intracellular staining for OVA (Fig. 5 B).
Isolation of the CD11c  DCs from spleen and lymph
nodes 15 h after injection of  DEC-205:OVA with or
without  CD40 confirmed that these DCs could present
the captured OVA to TCR-transgenic T cells (Fig. 5 C).
When  DEC-205:OVA was compared with a 1,000-fold
higher dose of soluble OVA (each given together with
 CD40), the former was presented much more vigorously
by DCs from systemic lymphoid tissues (Fig. 5 D). These
Figure 4. Enhanced efficacy
of  DEC-205:OVA plus  CD40
relative to other immunization
approaches. (A) C57BL/6 mice
were immunized s.c. with several
methods: Spleen DC pulsed ex
vivo with 10  g/ml each of
 DEC-205:OVA and  CD40;
500   g OVA in CFA; 50  g
OVA with 25  g   CD40; 50
 g of SIINFEKL peptide with
25   g   CD40; or 50 ng of
OVA in  DEC-205:OVA with
25   g of  CD40. 7 or 30 d
later, lymph nodes were harvested
and T cell expansion evaluated
by Kb-SIINFEKL–PE tetramer
and CD62L staining. The gate
for the y-axis was placed relative
to the CD62L-negative tetramer
binding cells in the right panel.
Indicated percentages are percent
of CD8  lymphocytes. (B) As in
A, but IFN-  secretion evalu-
ated by intracellular cytokine
staining. Data are means of three
experiments.Improved Vaccination with DC Antigen Targeting 820
results indicate that low doses of intracutaneous anti-DC
antibodies rapidly target along with an associated antigen
systemically to DCs in lymphoid tissues for days.
Prolonged Presentation of MHC Class I–Peptide Complexes
on Antigen-targeted DCs. To investigate the persistence of
MHC–OVA peptide complexes in vivo, we pretreated
mice with  DEC-205:OVA or OVA, each with or with-
out  CD40, for 1, 3, 7, 15, or 30 d before transferring
CFSE-labeled OT-I OVA-specific T cells. Surprisingly,
given the evidence that the half life of DCs in lymph nodes
is  1.5–2 d (35, 36), presentation was still vigorous in the
lymph nodes 15 d (but not 30 d; unpublished data) after
immunization with just 50 ng of OVA in  DEC-205:OVA
conjugates (Fig. 6 A, top left). Co-administration of
 CD40 slightly increased the presentation, especially at day
15. In contrast, proliferation elicited by administration of
50  g of soluble OVA or 50  g of preprocessed peptide
(unpublished data), was minimally detectable at 7 d after
injection, even if coadministered with  CD40 (Fig. 6 A,
bottom left). Likewise, when mice were primed with ex
vivo–loaded   CD40-matured splenic DCs, presentation
was not detectable beyond 3 d after injection (Fig. 6 A, top
right). If a high dose of OVA protein (500  g) was admin-
istered in CFA, proliferation also was detectable 15 d after
administration (Fig. 6 A, bottom right; as was the case for
50 ng of DEC-205–targeted OVA in CFA; unpublished
data), probably because the oily CFA emulsion allows the
depot of injected antigen to persist. In contrast to MHC
class I, MHC class II–peptide complexes were no longer
detectable at 7 d after injection of  DEC-205:OVA (Fig. 6
B). To test if the superiority of MHC class I presentation
was due to an expanded OVA-specific CD8  T cell reper-
toire, we immunized mice with preprocessed MHC class I
and II binding OVA peptides. If anything the MHC class
II–restricted response was greater (Fig. 6 C), suggesting that
 DEC-205 targeting seems to prioritize presentation on
MHC class I products. The results in Figs. 5 and 6 indicate
that the local injection of a single low dose of DC-targeted
antigen recreates a situation analogous to a systemic infec-
tion, with prolonged presentation of antigen in most lym-
phoid tissues.
DEC-205 Antigen Targeting As a Potential Vaccination
Strategy for Resistance to Tumors. We first studied resistance
to a B16 melanoma stably transduced with OVA (termed
MO4). We began with protection studies in which vacci-
nated mice were challenged at a distal site with MO4 cells
s.c., but this was done 2–3 mo after a single vaccination to
assess vaccine memory. The mice that received  DEC-
205:OVA conjugate in conjunction with  CD40 were
protected against a subsequent administration of 5   106
tumor cells 2–3 mo later (Fig. 7 A), while mice that re-
ceived only one component of the vaccine (antigen or ad-
juvant) or the isotype conjugate were not (unpublished
data). This protection was specific for OVA, as the vacci-
nated mice were not protected against an identical tumor
line (B16) that did not express OVA (unpublished data).
Figure 5. Systemic antigen
presentation after DEC-205 tar-
geting in situ. (A) C57BL/6 mice
were given 10  g of Alexa488-
conjugated antibodies s.c. At the
indicated time points, CD11c 
cells were enriched from the
draining or distal lymph nodes or
spleen for evaluation by flow cy-
tometry. The frequencies of DCs
capturing the injected Igs are
shown, and the DEC-205 and
CD8 high subset of splenic DCs
arrowed. (B) C57BL/6 mice were
given 10  g of  DEC-205:OVA,
isotype:OVA, or PBS s.c. and,
after 18 h, CD11c  cells were
enriched from draining or distal
lymph nodes or spleen. The
presence of OVA was evaluated
by intracellular staining with
Alexa488-conjugated   OVA and
flow cytometry. (C) 15 h after
s.c. treatment with 5  g of
 DEC-205:OVA or the isotype
conjugate      CD40, CD11c 
lymph node or spleen DCs were
selected and used to stimulate
OT-I T cells without further
addition of OVA. (D) As in C,
but mice were treated with
 CD40 and either  DEC-
205:OVA (5  g), OVA (500
 g), or PBS. Data are representa-
tive of at least two experiments.Bonifaz et al. 821
Studies with knockout mice determined that protection re-
quired DEC-205 expression, CD8  T cells and, to a lesser
extent, CD4  T cells (Fig. 7 A). We have not identified
the basis for the decreased resistance in CD4-depleted
mice, since there was no measurable difference in the fre-
quency of cytokine producing effectors between wild-type
and CD4 /  mice (unpublished data). We then tested DC
targeting in a more demanding therapeutic assay, in which
the OVA-bearing MO4 tumor cells were allowed to de-
velop into 0.5–1.0-cm-diameter tumors for 7 d before
treatment with different strategies. The combination of
 DEC-205:OVA in conjunction with  CD40 was able to
induce a therapeutic effect, and this was much superior to
other strategies, such as OVA in complete Freund’s adju-
vant and ex vivo–loaded DCs (Fig. 7 B).
DEC-205 Targeting of Antigens As a Potential Vaccination
Strategy for Mucosal Resistance.  To evaluate if mucosal im-
munity could be established by this new systemic vaccina-
tion approach, mice were immunized with 50 ng of OVA
conjugated to  DEC-205 together with  CD40 s.c., and 2
wk later, the animals were challenged with intranasal re-
combinant vaccinia OVA. Protection was observed at a
mucosal surface by measuring virus titres in the lung (Fig. 7
C), but in addition, the mice did not lose weight as a result
of infection (Fig. 7 D). In contrast, no protection was ob-
served relative to the PBS control if the animals had been
vaccinated with either the isotype conjugate or  DEC-
205:OVA or  CD40 alone (Fig. 7 C). Therefore a single
intracutaneous dose of only 50 ng of DC-targeted antigen
is effective in generating protective immunity, including at
a mucosal surface.
Discussion
Endocytic receptors are valuable targets to probe the
function of DCs within lymphoid tissues (19, 20). DCs
have a number of potential receptors for antigen uptake.
One, DEC-205/CD205, is known to be expressed in
abundance in situ (21–23), although more prominently on
certain DC subsets (33, 34). Antigens can be introduced
Figure 6. Prolonged MHC
class I, but not MHC class II,
presentation after DEC-205 tar-
geting in situ. (A) C57BL/6 mice
were immunized to OVA under
the conditions listed above each
panel for 15, 7, 3, or 1 d before
transferring 106 CFSE-labeled
OT-I T cells. Proliferation in the
lymph nodes was monitored by
flow cytometry 3 d later. (B) As
in A, but CFSE-labeled OT-I or
OT-II T cells were transferred.
(C) C57BL/6 mice were treated
with 50 ug MHC class I binding
peptide (SIINFEKL) in CFA, 50
 g MHC class II binding peptide
(LSQAVHAAHAEINEAGR) in
CFA, CFA alone, or PBS. IFN- 
secretion was evaluated after 12 d
in the lymph nodes as in Fig. 2 B.
Data are representative of at least
two experiments.
Figure 7. Immunization with a single low dose of  DEC-205:OVA and
 CD40 elicits resistance to OVA-modified pathogens. (A) C57BL/6 mice
were vaccinated as described in Fig. 3 A. 60 d later, mice were challenged
with 5   106 MO4 cells s.c. and tumor growth evaluated. (B) C57BL/6 mice
were inoculated with MO4 tumor cells as in (A). 7 d later, mice were treated
as in Fig. 4 A and tumor growth evaluated. (C) C57BL/6 mice were treated
as in Fig. 3 A. 30 d after vaccination, mice were challenged with 105 PFU of
vaccinia–OVA intranasally. 7 d later, lungs were harvested and virus titer
evaluated by a plaque-forming assay. (D) As in C, but mice were weighed
daily after viral challenge. Data are representative of at least two experiments.Improved Vaccination with DC Antigen Targeting 822
into  DEC-205 antibodies by genetic engineering (19) or
by chemical conjugation (20). The antigens then target se-
lectively to DCs, which in turn present peptides to CD4 
and CD8  T cells. Previous work with this approach has
focused on TCR-transgenic T cells, so that the number
and function of antigen-specific T cells could be more
readily followed (19, 20). Here we have used OVA as a
model to determine the consequences of antigen targeting
to DCs in naive mice with a polyclonal T cell repertoire,
including protective systemic immunity. In addition to
showing the efficacy of the antigen-targeting approach in
naive mice, we made some surprising findings with respect
to underlying mechanisms, and we found that antigen tar-
geting produces much stronger immunity than the standard
use of much higher doses (1,000-fold) of soluble antigen
with complete Freund’s adjuvant, including therapeutic tu-
mor immunity in an experimental system.
Our initial observation was that very small amounts of
antigen targeted to DCs were capable of inducing com-
bined CD4  and CD8  immunity, as long as a DC matu-
ration stimulus was also administered (Fig. 2). A subset of
DCs in lymph nodes already have the properties of mature
cells in the steady-state, including an inability to process a
new offering of a protein antigen (37). However, we
showed previously that some DEC-205  cells processed
and presented antigens in the steady-state but required ex-
posure to agonistic  CD40 antibody to induce immunity,
in keeping with their designation as “immature” (19, 20).
With respect to the stimuli for DC maturation in vivo, ad-
ditional experiments will be required to determine the rela-
tive value of CD40 ligation and other stimuli, such as
ligands for toll-like receptors. Nevertheless, when  CD40
was used with  DEC-205:OVA, immunity developed and
at high levels, particularly when compared with  CD40
and soluble OVA (Fig. 2). The strong and durable forma-
tion of effector memory cells with the combination of
 DEC-205:OVA and  CD40 is relevant for therapeutic
vaccination, but for protective vaccines, further studies of
central memory will be needed. Nevertheless, the en-
hanced immunity we observed with antigen-targeting pro-
vides additional evidence for a pivotal role of maturing
DCs in initiating immunity.
Interestingly, within 30 min of injection into the skin,
antibody gained access to many of its targets in the draining
lymph node, and also, the antibody moved into the efferent
lymph and blood to reach the large reservoir of spleen
DCs. Over slightly longer time periods (hours), the
 DEC-205 antibodies reached distal sites, such as the DCs
in mesenteric and mediastinal lymph nodes. In contrast, an-
tigen carriage by peripheral DCs would take  6 h, and
these DCs would not move past the draining lymph node
to reach other organs. The rapid antibody-mediated target-
ing of antigen to DCs systemically contrasts with nontar-
geted soluble protein, which primarily was presented in
draining lymphoid organs (Fig. 5 D). Antireceptor antibod-
ies are therefore valuable antigen-targeting vehicles, be-
cause they impart specificity to antigen delivery and impor-
tantly, they exploit the protein retrieval function of the
lymphatic system to distribute the antibody systemically to
large numbers of DCs in lymphoid tissues.
We also noted that DEC-205–targeted antigens were
presented for much longer times than expected (Fig. 6 A),
but primarily in the case of peptides complexed to MHC
class I rather than class II products (Fig. 6 B). The greater
sensitivity for class I presentation may not be due to inher-
ent differences in priming OVA-specific CD8  T cells rel-
ative to CD4  T cells, because when we injected prepro-
cessed MHC class I and II binding peptides with CFA, the
latter were more effective immunogens (Fig. 6 C). There-
fore DEC-205 targeting is more prominently enhancing
MHC class I presentation (Fig. 1) and for prolonged peri-
ods (Fig. 6). We speculate that this reflects certain features
of DEC-205. This receptor may be specialized to target an-
tigens to the exogenous pathway for antigen processing and
presentation on MHC class I (20), which likely entails the
fusion of elements of the rough endoplasmic reticulum
with endocytic vesicles (38, 39). Antigen also may persist in
these compartments for long periods and even be repro-
cessed by other DCs when the initial cells die (40). An ad-
ditional possibility is that there may be longer lived DEC-
205  DCs in intact lymph nodes. The half life of many
DCs is short,  2 d (35, 36), but previous turnover studies
may not have included these longer-lived DCs if they were
present but not isolated from lymph nodes. For example,
Garg et al. have recently shown that certain DEC-205 high
DCs derived from the skin can live for 2 wk after migration
to the lymph nodes (41). Importantly, a single s.c. injection
of DC-targeted antigen seems to recreate what would be
seen in many systemic infections, the presence and presen-
tation of antigen in multiple lymphoid sites including me-
senteric lymph nodes and spleen.
We would like to suggest that the appropriate targeting
of antigen to DCs has the potential to improve vaccine de-
sign. Antibody-mediated targeting of antigens to these
cells, coupled with an effective maturation stimulus, pro-
vides an alternative to more empirical approaches to pro-
tein and subunit vaccines. To date, only antibodies to the
DEC-205 antigen uptake receptor (24, 25) have been
tested, so it is unclear whether targeting to endocytic re-
ceptors, and this receptor in particular, is essential. We are
finding that it is possible to engineer protein antigens into
the   -DEC-205 antibody (here we have used protein
chemically conjugated to monovalent DEC-205 antibody
fragments), which should make it feasible to vaccinate with
a group of antibodies to deliver a mixture of proteins from
microbial agents and tumors. Because of the ability of this
vaccination approach to prime cytolytic CD8  T cells, and
because DCs in vivo should efficiently present additional
antigens from targets killed by these T cells (40, 42, 43), the
immunity may be broadened even further, especially in the
setting of tumor immunotherapy.
The development of vaccines capable of more effective
induction of T cell–mediated immunity represents a major
challenge for global health. More effective harnessing ofBonifaz et al. 823
DCs, which are nature’s adjuvants for inducing immunity,
is one strategy to improve vaccine design. Targeting of an-
tigens via  DEC-205 antibodies to maturing DCs results in
CD8  T cell immunity that is stronger than other ap-
proaches (Figs. 3 and 4), and it is associated with efficacy in
relatively demanding systemic and mucosal models of pro-
tective immunity (Fig. 7), possibly because of the systemic
and prolonged presentation of antigens. The data at this
juncture pertain to an experimental protein antigen, OVA,
but this new approach to vaccination markedly enhances
immunity and protection relative to alternative, actively
used approaches. The latter involve DCs charged ex vivo
with antigen and antigen administered together with com-
plete Freund’s adjuvant. We are now engineering clinically
relevant antigens into the  -DEC-antibody to further ad-
dress the proposal that appropriately targeted vaccines, by
directly harnessing large numbers of maturing DCs, will
greatly improve vaccine efficacy.
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